Dr. Scott D. Lee
Gastroenterology (Gastroenterology Physician)
University Of Washington Medical Ctr, 1959 Ne Pacific St
Seattle, WA 98195
Who else practices at this address →
King County includes primary care (5% of residents) and dental (4% of residents) and mental health (4% of residents) shortage areas. About shortage areas
- Medicare participating
At a glance
- Medical school
- Jefferson Medical College of Thomas Jefferson University (1994)
- Years since graduation
- 32
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 167
Licensed in Washington since 1997, according to the Washington State Department of Health. We show license dates only for the states that publish them in bulk; see which states do. For other states, check the state medical board.
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 1994Medical school: Jefferson Medical College of Thomas Jefferson University
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Gastroenterology Physician primary
WA license MD00034847 (first issued 1997; active)
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- University of Washington Medical Ctr Seattle, WA
Medical groups
- The Association of University Physicians (3,535 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 167
- Services billed
- 419
- Patients’ average age
- 69
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 40-54 minutes | 64 | 49 |
| Biopsy of large bowel using a flexible endoscope | 48 | 48 |
| Established patient office or other outpatient visit, 30-39 minutes | 37 | 30 |
| Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 12 | 12 |
| Removal of polyps or growths of large bowel using an endoscope with mechanical snare | 12 | 12 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Stelara (ustekinumab) | 104 |
| Diphenoxylate-Atropine (diphenoxylate hcl/atropine) Other prescribers in Seattle, WA | 41 |
| Rinvoq (upadacitinib) | 34 |
| Methotrexate (methotrexate sodium) Other prescribers in Seattle, WA | 33 |
| Lactated Ringers (ringer's solution,lactated) | 29 |
| Humira(Cf) Pen (adalimumab) Other prescribers in Seattle, WA | 28 |
| Sod Sulf-Potass Sulf-Mag Sulf (sodium, potassium,mag sulfates) Other prescribers in Seattle, WA | 27 |
| Pantoprazole Sodium Other prescribers in Seattle, WA | 26 |
| Omeprazole Other prescribers in Seattle, WA | 25 |
| Folic Acid Other prescribers in Seattle, WA | 18 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 7 companies reported 145 payments worth $30,697 in total to this clinician.
| Janssen Biotech, Inc. | $12,014 |
|---|---|
| Merck Sharp & Dohme LLC | $9,814 |
| Celltrion USA Inc. | $4,241 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $3,500 |
| AbbVie Inc. | $957 |
| Celltrion, Inc. | $150 |
| Takeda Pharmaceuticals U.S.A., Inc. | $21.00 |
| Consulting Fee | $22,456 |
|---|---|
| Food and Beverage | $4,344 |
| Travel and Lodging | $3,897 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Merck Sharp & Dohme LLC Jul 9, 2025 | Consulting FeeCompany’s descriptionPayment made to Third Party Organization not to Physician. | $7,040 |
| Celltrion USA Inc. May 5, 2025 | Consulting Fee ZYMFENTRA · GASTROENTEROLOGY | $4,075 |
| Janssen Biotech, Inc. May 10, 2025 | Consulting Fee TREMFYA · Immunology | $3,600 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Dec 8, 2025 | Consulting Fee | $3,500 |
| Janssen Biotech, Inc. Dec 15, 2025 | Consulting Fee TREMFYA · Immunology | $3,375 |
| AbbVie Inc. Dec 5, 2025 | Consulting Fee SKYRIZI · IMMUNOLOGY | $700 |
| Merck Sharp & Dohme LLC Sep 11, 2025 | Travel and Lodging IMMUNOLOGY · travel to Denver, CO · in-kind Company’s descriptionProvided as part of a clinical research engagement. | $690 |
| Merck Sharp & Dohme LLC Apr 3, 2025 | Travel and Lodging IMMUNOLOGY · travel to Dallas, TX · in-kind | $566 |
| Janssen Biotech, Inc. Dec 6, 2025 | Travel and Lodging TREMFYA · Immunology · travel to ORLANDO, FL · in-kind | $527 |
| Janssen Biotech, Inc. Dec 6, 2025 | Travel and Lodging TREMFYA · Immunology · travel to ORLANDO, FL · in-kind | $409 |
All 20 payments other than meals, newest first
| Company | What it was for | Amount |
|---|---|---|
| Janssen Biotech, Inc. Dec 15, 2025 | Consulting Fee TREMFYA · Immunology | $3,375 |
| Merck Sharp & Dohme LLC Dec 13, 2025 | Travel and Lodging IMMUNOLOGY · travel to Denver, CO · in-kind Company’s descriptionProvided as part of a clinical research engagement. | $131 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Dec 8, 2025 | Consulting Fee | $3,500 |
| Janssen Biotech, Inc. Dec 6, 2025 | Travel and Lodging TREMFYA · Immunology · travel to ORLANDO, FL · in-kind | $527 |
| Janssen Biotech, Inc. Dec 6, 2025 | Travel and Lodging TREMFYA · Immunology · travel to ORLANDO, FL · in-kind | $409 |
| Janssen Biotech, Inc. Dec 6, 2025 | Travel and Lodging TREMFYA · Immunology · travel to ORLANDO, FL · in-kind | $288 |
| AbbVie Inc. Dec 5, 2025 | Consulting Fee SKYRIZI · IMMUNOLOGY | $700 |
| Merck Sharp & Dohme LLC Sep 11, 2025 | Travel and Lodging IMMUNOLOGY · travel to Denver, CO · in-kind Company’s descriptionProvided as part of a clinical research engagement. | $690 |
| Merck Sharp & Dohme LLC Sep 11, 2025 | Travel and Lodging IMMUNOLOGY · travel to Denver, CO · in-kind Company’s descriptionProvided as part of a clinical research engagement. | $210 |
| Merck Sharp & Dohme LLC Jul 9, 2025 | Consulting FeeCompany’s descriptionPayment made to Third Party Organization not to Physician. | $7,040 |
| Merck Sharp & Dohme LLC Jul 9, 2025 | Travel and Lodging travel to Dallas, TX Company’s descriptionPayment made to Third Party Organization not to Physician. | $150 |
| Janssen Biotech, Inc. May 10, 2025 | Consulting Fee TREMFYA · Immunology | $3,600 |
| Celltrion USA Inc. May 5, 2025 | Consulting Fee ZYMFENTRA · GASTROENTEROLOGY | $4,075 |
| Celltrion USA Inc. May 5, 2025 | Consulting Fee ZYMFENTRA · GASTROENTEROLOGY · in-kind | $150 |
| Celltrion USA Inc. May 5, 2025 | Consulting Fee ZYMFENTRA · GASTROENTEROLOGY · in-kind | $16.42 |
| Merck Sharp & Dohme LLC Apr 4, 2025 | Travel and Lodging IMMUNOLOGY · travel to Dallas, TX · in-kind | $317 |
| Merck Sharp & Dohme LLC Apr 4, 2025 | Travel and Lodging IMMUNOLOGY · travel to Dallas, TX · in-kind | $116 |
| Merck Sharp & Dohme LLC Apr 3, 2025 | Travel and Lodging IMMUNOLOGY · travel to Dallas, TX · in-kind | $566 |
| Merck Sharp & Dohme LLC Apr 3, 2025 | Travel and Lodging IMMUNOLOGY · travel to Dallas, TX · in-kind | $316 |
| Janssen Biotech, Inc. Jan 17, 2025 | Travel and Lodging TREMFYA · Immunology · travel to LAKE BUENA VISTA, FL | $179 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 6 industry-funded studies in 2025, from 3 companies. The companies reported $99,232 in research payments for these studies, mostly to the institutions running them.
- A Phase IIa, randomised, double-blind, placebo-controlled trial to evaluate the safety, efficacy, pharmacokinetics and pharmacodynamics of BI 706321 orally administered for 12 weeks in patients with Crohn`s Disease (C…
Boehringer Ingelheim International GmbH - A Maintenance and Long-Term Extension Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Participants With Crohn's Disease Who Completed the Studies M14-431 or M14-433
AbbVie Inc. · Active, not recruiting · NCT03345823 - Phase IIa, single arm exploratory clinical trial to evaluate safety, tolerability pharmacokinetics, pharmacodynamics, and clinical effect, of 12-week induction treatment with BI 3032950 in patients with moderate to se…
Boehringer Ingelheim International GmbH - M14-430 - A Maintenance and Long-Term Extension Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Participants With Crohn Disease Who Completed the Studies M14-431 or M14-433
AbbVie Inc. - A Long-Term Registry of Humira (Adalimumab) in Patients With Moderately to Severely Active Ulcerative Colitis (UC)
AbbVie Inc. - Proof of Clinical Principal in Crohn's Disease
Boehringer Ingelheim Pharma GmbH & Co.kg
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.